An antibody lacking an Fc domain selected from the group consisting of a scFv, an affibody, a V H domain, a V L domain, a V-NAR domain and a V H H domain, comprising a TGase recognition tag comprising a functionalized acceptor glutamine residue of the TGase recognition tag linked to a lysine-based linker as shown in Formula IV, below, -NH- n -X-L-(V-(Y-(M or Z) z) q) r Formula IV where: Q is glutamine residue present in the TGase recognition tag; n is a substituted or unsubstituted alkyl or heteroalkyl chain, optionally wherein any carbon of the chain is substituted with an alkoxy, hydroxyl, alkylcarbonyloxy, alkyl-S-, thiol, alkyl-C S-,, amine, alkylamine, amide, or alkylamide; n is an integer selected from among the range of 2 to 20; X is NH, O, S, absent, or a bond; L is independently absent, a bond or a continuation of a bond, or a carbon comprising framework of 5 to 200 atoms substituted at one or more atoms, optionally, wherein the carbon comprising framework comprises a linear framework of 5 to 30 carbon atoms optionally substituted at one or more atoms, optionally wherein the carbon comprising framework is a linear hydrocarbon, a symmetrically or asymmetrically branched hydrocarbon, monosaccharide, disaccharide, linear or branched oligosaccharide (asymmetrically branched or symmetrically branched), other natural linear or branched oligomers (asymmetrically branched or symmetrically branched), or a dimer, trimer, or higher oligomer (linear, asymmetrically branched or symmetrically branched) resulting from any chain-growth or step-growth polymerization process; r is an integer selected from among 1, 2, 3 or 4; q is an integer selected from among 1, 2, 3 or 4; z is an integer selected from among 1, 2, 3 or 4; and V is independently absent, a non-cleavable moiety or a conditionally-cleavable moiety; Y is independently absent, a bond or a continuation of a bond, or a spacer system which is comprised of 1 or more spacers; Z is a moiety-of-interest, optionally a moiety that improves the pharmacokinetic properties, or a therapeutic moiety or a diagnostic moiety; and M is independently: R or ((RR') - L' - (V'-(Y'- z') q') r'), wherein R is a reactive moiety, wherein each of L', V', Y', z', q', and r' are as defined as L, V, Y, z, q and r, and wherein RR' is an addition product between an R and a reactive group R' complementary for forming at least one bond with reactive group R. Q is glutamine residue present in the TGase recognition tag; n is a substituted or unsubstituted alkyl or heteroalkyl chain, optionally wherein any carbon of the chain is substituted with an alkoxy, hydroxyl, alkylcarbonyloxy, alkyl-S-, thiol, alkyl-C S-,, amine, alkylamine, amide, or alkylamide; n is an integer selected from among the range of 2 to 20; X is NH, O, S, absent, or a bond; L is independently absent, a bond or a continuation of a bond, or a carbon comprising framework of 5 to 200 atoms substituted at one or more atoms, optionally, wherein the carbon comprising framework comprises a linear framework of 5 to 30 carbon atoms optionally substituted at one or more atoms, optionally wherein the carbon comprising framework is a linear hydrocarbon, a symmetrically or asymmetrically branched hydrocarbon, monosaccharide, disaccharide, linear or branched oligosaccharide (asymmetrically branched or symmetrically branched), other natural linear or branched oligomers (asymmetrically branched or symmetrically branched), or a dimer, trimer, or higher oligomer (linear, asymmetrically branched or symmetrically branched) resulting from any chain-growth or step-growth polymerization process; r is an integer selected from among 1, 2, 3 or 4; q is an integer selected from among 1, 2, 3 or 4; z is an integer selected from among 1, 2, 3 or 4; and V is independently absent, a non-cleavable moiety or a conditionally-cleavable moiety; Y is independently absent, a bond or a continuation of a bond, or a spacer system which is comprised of 1 or more spacers; Z is a moiety-of-interest, optionally a moiety that improves the pharmacokinetic properties, or a therapeutic moiety or a diagnostic moiety; and M is independently: R or ((RR') - L' - (V'-(Y'- z') q') r'), wherein R is a reactive moiety, wherein each of L', V', Y', z', q', and r' are as defined as L, V, Y, z, q and r, and wherein RR' is an addition product between an R and a reactive group R' complementary for forming at least one bond with reactive group R.